A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..

Inclusion criteria

• Signed informed consent.
• Age ≥18 and ≤65 years old;
• Body mass index (BMI) ≥18 and ≤ 30 kg/m2;
• Subjects who are receiving statin therapy at the time of screening or who are eligible for statin therapy can receive a stable dose of statin therapy for more than 28 days before randomization and are willing to maintain stable statin therapy during the study;
• Low-density lipoprotein cholesterol (LDL-C) level ≥2.6mmol/L for subjects who are receiving statin and/or other lipid-lowering therapy at the time of screening, or LDL-C≥ 4.1mmol/L for subjects who didn't receive any-lowering therapy at the time of screening, and LDL-C still ≥2.6mmol/L before randomization;
• Fasting triglycerides ≤4.5 mmol/L;

Exclusion criteria

• Diagnosis of homozygous familial hypercholesterolemia;
• History of New York heart association (NYHA) defined Ⅱ - Ⅳ heart failure;
• History of uncontrolled arrhythmiast;
• History of myocardial infarction, history of PTCA or PCI or CABG, history of unstable angina befor 90 days of randomization;
• History of stroke or TIA；
• Uncontrolled hypertension with SBP≥160mmHg and/or DBP≥100mmHg
• Type 1 diabetes, or type 2 diabetes that is or poorly controlled（HbA1c> 8.0%);